Alder BioPharma (ALDR) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Piper Jaffray Starts Alder Biopharm (ALDR) at Overweight
October 31, 2016 6:13 AM EDTPiper Jaffray initiates coverage on Alder Biopharm (NASDAQ: ALDR) with a Overweight rating and a price target of $47.00.
Analyst Charles Duncan commented, "We are initiating coverage on Alder with an OW rating and $47 PT based on risk-adjusted value of its anti-CGRP candidate ALD403... More
